SCHEMBL6617033

SCHEMBL6617033

c1ccc(CCc2cnc3cc4[nH]ncc4cc3n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 9/20 0.49
▸ GSK3B P49841 5/20 0.49
▸ AURKB Q96GD4 5/20 0.49
▸ JAK2 O60674 4/20 0.49
▸ PDE10A Q9Y233 4/20 0.45
▸ FGFR3 P22607 1/20 0.43
▸ ROCK1 Q13464 6/20 0.41
▸ CDK5 Q00535 3/20 0.40
▸ DYRK1A Q13627 3/20 0.40
▸ FGFR1 P11362 2/20 0.40
▸ AURKA O14965 2/20 0.40
▸ DAPK3 O43293 2/20 0.40
▸ CDK1 P06493 2/20 0.40
▸ PRKACA P17612 2/20 0.40
▸ CDK2 P24941 2/20 0.40
▸ MARK3 P27448 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ GSK3A P49840 2/20 0.40
▸ CDC42BPA Q5VT25 2/20 0.40
▸ RPS6KB1 P23443 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6617440 1.00 ROCK2 (0.49) ROCK2GSK3BAURKBJAK2PDE10A
SCHEMBL8118257 0.95 ROCK2 (0.46) ROCK2GSK3BAURKBJAK2PDE10A
SCHEMBL6618464 0.88 ROCK2 (0.49) ROCK2GSK3BAURKBJAK2ROCK1
SCHEMBL6618856 0.88 ROCK2 (0.49) ROCK2GSK3BAURKBJAK2ROCK1
SCHEMBL6618548 0.84 MKNK1 (0.43) ROCK2GSK3BAURKBJAK2ROCK1
SCHEMBL6616873 0.84 MKNK1 (0.43) ROCK2GSK3BAURKBJAK2ROCK1
SCHEMBL6615880 0.81 CYSLTR1 (0.46) GSK3BPDE10AFGFR3CDK5DYRK1A
SCHEMBL6616216 0.81 CYSLTR1 (0.46) GSK3BPDE10AFGFR3CDK5DYRK1A
SCHEMBL6615711 0.79 L3MBTL1 (0.39) GSK3BCDK5DYRK1AFGFR1CDK2
SCHEMBL6616860 0.79 L3MBTL1 (0.39) GSK3BCDK5DYRK1AFGFR1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0779889-B1 PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE AVENTIS PHARMA INC (US) 2004-06-23 — — EP disclosed
US-5476851-A Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1995-12-19 — — US disclosed
Send feedback